A COMPARATIVE TRIAL OF A LOW-MOLECULAR-WEIGHT HEPARIN (ENOXAPARIN) VERSUS STANDARD HEPARIN FOR THE PROPHYLAXIS OF POSTOPERATIVE DEEP-VEIN THROMBOSIS IN GENERAL-SURGERY
Mt. Nurmohamed et al., A COMPARATIVE TRIAL OF A LOW-MOLECULAR-WEIGHT HEPARIN (ENOXAPARIN) VERSUS STANDARD HEPARIN FOR THE PROPHYLAXIS OF POSTOPERATIVE DEEP-VEIN THROMBOSIS IN GENERAL-SURGERY, The American journal of surgery, 169(6), 1995, pp. 567-571
BACKGROUND: Various studies have been performed in general surgery pat
ients comparing low molecular weight heparin (LMWH) with standard hepa
rin (SH) for the prevention of postoperative deep vein thrombosis (DVT
), revealing contradicting results, Therefore, we have compared the ef
ficacy and safety of a LMWH for the prevention of DVT after major gene
ral surgery, PATIENTS AND METHODS: Patients received either 20 mg LMWH
(enoxaparin) once daily, or 5,000 IU SH TID, starting preoperatively
in a prospective, randomized, double-blind international multicenter t
rial. DVT was diagnosed using fibrinogen I 125 leg scanning. Major and
minor bleeding were assessed clinically. RESULTS: A total of 718 pati
ents were randomized to LMWH, and 709 patients to SH. DVT was detected
in 58 LMWH-treated patients (8.1%, 95% confidence interval [CI] 6.2%
to 10.3%) and in 45 patients allocated to SH (6.3%, 95% CI 4.7% to 8.4
%, P >0.05) Major bleeding complications occurred in 11 LMWH-treated p
atients (1.5%, 95% CI 0.8% to 2.7%) and in 18 patients to whom standar
d heparin was administered (2.5%, 95% CI 1.5% to 3.9%, P >0.05), Four
LMWH-treated patients (0.6%) required reoperation for bleeding as comp
ared to 13 patients in the SH group (1.8%, P = 0.03), CONCLUSION: This
LMWH appeared as effective and safe as SH. In view of its more conven
ient way of administration, this LMWH might be preferred for thrombopr
ophylaxis.